The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of 133536 isoform, 13353 isoform, or both 133536 and 13353 isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in 133536 isoform, 13353 isoform, or both 133536 and 13353 isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing 133p536 isoform, 13353 isoform, or both 133536 and 13353 isoforms expression; and also to screening methods for anti-cancer stem cells agents.

Disclosed is the in vitro use of at least one lectin for marking cancer stem cells of hormone-dependent cancer target organs, selected from the lectins Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I) and Griffonia simplicifolia lectin II (GSL-II), in particular at least two lectins selected from MAH-II, EEL, PTL-I and GSL-II, in particular the two lectins MAH-II and EEL, in order to obtain cancer stem cells of labeled hormone-dependent cancer target organs in a biological sample.

The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

A method of detecting serous ovarian cancer, particularly early stage serous ovarian cancer is described. The method uses up to sixteen compounds found in the blood serum of a person, and determines that changes of some portion of these sixteen compounds can determine the presence of serous ovarian cancer in a women with up to 100% accuracy, specificity, and sensitivity.

The invention relates to linkers and methods for generating arrays with linkers. The invention also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for epitope identification, drug discovery and as analytical tools. The invention provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing cancer.

The present invention relates to a unipotent neutrophil progenitor population, to methods of preparing and using same. In certain embodiments, the neutrophil progenitor population have at least the phenotype CD45+, CD41, CD127(IL-7R), CD19, CD3, CD161 (NK1.1), CD169 (Siglec 1), CD11c, Siglec 8, FcRI and CD115 (CSF-1R).

Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject, and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.

Immune checkpoint inhibitors (ICI) have revolutionized therapy for advanced cancer, however many patients still do not respond to treatment. However, the efficacy and effectiveness of these therapies varies greatly across individual patients and among different tumour types. A substantial unmet need is thus the development of biomarkers of response to ICI, in order to identify, before initiation of treatment, which patients are likely to experience a response to and clinical benefit from such treatments. Here, the inventors analyzed SPHK1 mRNA in tumor biopsies by in situ hybridization using the RNAscope technology in a cohort of 32 patients suffering from metastatic melanoma. They showed that elevated expression of SPHK1, encoding sphingosine kinase 1 (SK1), which produces the oncometabolite sphingosine-1-phosphate (S1P) is associated with a poor survival in metastatic melanoma patients treated with to the well-known immune-checkpoint inhibitor anti-PD-1 antibody. Accordingly, the present invention relates to the use of SK1 as biomarker for predicting response to immune-checkpoint inhibitors.

Disclosed are compounds having formula (I):

##STR00001##

or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4, Y.sup.5, Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, Z.sup.5, Z.sup.6 are each as defined in the specification; compositions thereof; uses thereof; and methods of use thereof.